APDN — Applied DNA Sciences Share Price
Last trade - 00:00- $5.83m
- $2.36m
- $13.37m
- 16
- 48
- 31
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.38 | ||
| Price to Tang. Book | 3.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.65 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -184.61% | ||
| Return on Equity | -108.8% | ||
| Operating Margin | -150.33% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.39 | 1.93 | 9.03 | 18.17 | 13.37 | 5.02 | 8.17 | 27.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Directors
- James Hayward CHM (68)
- Beth Jantzen CFO (44)
- Judith Murrah COO (63)
- Clay Shorrock OTH (37)
- Scott Anchin IND (47)
- John Bitzer IND (60)
- Robert Catell IND (84)
- Joseph Ceccoli IND (58)
- Elizabeth Ferguson IND (70)
- Yacov Shamash IND (71)
- Sanford Simon IND (78)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 17th, 2008
- Public Since
- August 24th, 2001
- No. of Shareholders
- 133
- No. of Employees
- 53
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,978,703
- Address
- 50 Health Sciences Drive, STONY BROOK, 11790
- Web
- https://adnas.com/
- Phone
- +1 6312408800
- Contact
- Sanjay Hurry
- Auditors
- Marcum LLP
Latest News for APDN
Upcoming Events for APDN
Q2 2024 Applied DNA Sciences Inc Earnings Release
Q3 2024 Applied DNA Sciences Inc Earnings Release
Applied DNA Sciences Inc Annual Shareholders Meeting
Similar to APDN
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:02 UTC, shares in Applied DNA Sciences are trading at $0.34. This share price information is delayed by 15 minutes.
Shares in Applied DNA Sciences last closed at $0.34 and the price had moved by -67.01% over the past 365 days. In terms of relative price strength the Applied DNA Sciences share price has underperformed the S&P500 Index by -72.55% over the past year.
The overall consensus recommendation for Applied DNA Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Applied DNA Sciences does not currently pay a dividend.
Applied DNA Sciences does not currently pay a dividend.
Applied DNA Sciences does not currently pay a dividend.
To buy shares in Applied DNA Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.34, shares in Applied DNA Sciences had a market capitalisation of $5.83m.
Here are the trading details for Applied DNA Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: APDN
Based on an overall assessment of its quality, value and momentum Applied DNA Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Applied DNA Sciences is $2.25. That is 555.79% above the last closing price of $0.34.
Analysts covering Applied DNA Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied DNA Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -67.99%.
As of the last closing price of $0.34, shares in Applied DNA Sciences were trading -62.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Applied DNA Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Applied DNA Sciences' management team is headed by:
- James Hayward - CHM
- Beth Jantzen - CFO
- Judith Murrah - COO
- Clay Shorrock - OTH
- Scott Anchin - IND
- John Bitzer - IND
- Robert Catell - IND
- Joseph Ceccoli - IND
- Elizabeth Ferguson - IND
- Yacov Shamash - IND
- Sanford Simon - IND